361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
Publication
, Conference
Wu, C; Strickler, JH; Cercek, A; Siena, S; André, T; Ng, K; Van Cutsem, E; Paulson, AS; Hubbard, J; Coveler, A; Fountzilas, C; Kardosh, A ...
Published in: Annals of Oncology
September 2022
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2022
Volume
33
Start / End Page
S700 / S701
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Wu, C., Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., … Bekaii-Saab, T. (2022). 361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. In Annals of Oncology (Vol. 33, pp. S700–S701). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.499
Wu, C., J. H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, et al. “361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER.” In Annals of Oncology, 33:S700–701. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.499.
Wu C, Strickler JH, Cercek A, Siena S, André T, Ng K, et al. 361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. In: Annals of Oncology. Elsevier BV; 2022. p. S700–1.
Wu, C., et al. “361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S700–01. Crossref, doi:10.1016/j.annonc.2022.07.499.
Wu C, Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Paulson AS, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez Fernandez ME, Hsu L-I, Stecher M, Zhao K, Bekaii-Saab T. 361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER. Annals of Oncology. Elsevier BV; 2022. p. S700–S701.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2022
Volume
33
Start / End Page
S700 / S701
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis